Claims
- 1. Heterocyclic compounds of the formula (1): ##STR162## wherein ring ##STR163## is a ##STR164## wherein Y is single bond or C1-6 alkylene;
- Z is single bond, or C1-2 alkylene or vinylene;
- E is
- (i) 4-15 membered, unsaturated, partially saturated or fully saturated, mono or bicyclic hetero ring containing as hetero atoms, one or two nitrogen atoms, one or two oxygen atoms or one sulfur atom,
- (ii) 4-15 membered, unsaturated or partially saturated, mono or bicyclic carbocyclic ring, or
- (iii) --OR.sup.4 (in which R.sup.4 is hydrogen atom, C1-4 alkyl or C1-4 alkyl substituted by a hydroxy group);
- Cyc is 5-7 membered, unsaturated, partially saturated or fully saturated, monocyclic hetero ring containing as hetero atoms, one or two nitrogen atoms or 5-7 membered, unsaturated or partially saturated, monocyclic carbocyclic ring;
- R.sup.1 is hydrogen atom or C1-4 alkyl;
- R.sup.2 is hydrogen atom, C1-4 alkyl, C1-4 alkoxy or halogen atom;
- R.sup.3 is hydrogen atom, C1-4 alkyl, C1-4 alkoxy or --COOR.sup.5 (in which R.sup.5 is hydrogen atom or C1-4 alkyl);
- with the proviso that
- (1) a Cyc ring should not bond to Z through a nitrogen atom in the Cyc ring when Z is vinylene and that
- (2) Y is not a single bond, when E is --OR.sup.4 ;
- or pharmaceutically acceptable acid addition salts thereof, pharmaceutically acceptable salts thereof, or hydrates thereof.
- 2. A compound according to claim 1, wherein Cyc is 7-membered, unsaturated, partially saturated or fully saturated, monocyclic hetero ring containing as hetero atoms, one or two nitrogen atoms.
- 3. A compound according to claim 1, wherein Cyc is 6-membered, unsaturated, partially saturated or fully saturated, monocyclic hetero ring containing as hetero atoms, one or two nitrogen atoms.
- 4. A compound according to claim 1, wherein Cyc is 5-membered, unsaturated, partially saturated or fully saturated, monocyclic hetero ring containing as hetero atoms, one or two nitrogen atoms.
- 5. A compound according to claim 1, wherein Cyc is 5-7 membered, unsaturated or partially saturated, monocyclic carbocyclic ring.
- 6. A compound according to claim 1, wherein E is --OR.sup.4.
- 7. A compound according to claim 1, wherein E is 4-15 membered, unsaturated, partially saturated or fully saturated, mono or bicyclic hetero ring containing as hetero atoms, one or two nitrogen atoms, one or two oxygen atoms or one sulfur atom.
- 8. A compound according to claim 1, wherein E is 4-15 membered, unsaturated or partially saturated, mono or bicyclic carbocyclic ring.
- 9. A compound according to claim 1, which is ##STR165## wherein Y is methylene, E is phenyl, Z is single bond, Cyc is phenyl and R.sup.3 is hydrogen atom;
- or pharmaceutically acceptable acid addition salts thereof, pharmaceutically acceptable salts thereof, or hydrates thereof.
- 10. A pharmaceutical composition for the treatment of mammals, which comprises, as active ingredient, an effective amount of a compound of the formula (1) as claimed in claim 1, pharmaceutically acceptable acid addition salts thereof, pharmaceutically acceptable salts thereof, or hydrates thereof; and a pharmaceutically acceptable carrier.
- 11. The pharmaceutical composition according to claim 10, wherein the mammal is a human.
Parent Case Info
This application is a divisional of U.S. patent application Ser. No. 08/393,995, filed Feb. 24, 1995 now U.S. Pat. No. 5,869,486.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5011835 |
Peet et al. |
Apr 1991 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
393995 |
Feb 1995 |
|